Direkt zum Inhalt
Merck

Valproic acid-induced acute pancreatitis and multiorgan failure in a child.

Pediatric emergency care (2013-05-04)
Ayhan Yaman, Tanl Kendirli, Cağlar Odek, Omer Bektaş, Zarife Kuloğlu, Meltem Koloğlu, Erdal Ince, Gülhis Deda
ZUSAMMENFASSUNG

Valproic acid (VPA) is still an important antiepileptic drug, with the broadest spectrum used in all types of seizures and syndromes. It has serious adverse effects such as hepatotoxicity, hyperammonemic encephalopathy, coagulation disorders, and pancreatitis. The incidence of VPA-associated pancreatitis has been estimated to be 1:40,000. We present a 6-year-old boy who developed acute pancreatitis (AP) and multiple-organ failure after 3 months of VPA therapy. The patient's laboratory values showed that his kidney and hepatic function had impaired and thrombocytopenia, and coagulopathy had developed. The patient's abdominal tomography showed a suspected appearance, which was consistent with pancreatitis. Because amylase and lipase levels were found to be high, AP was considered. The patient improved after cessation of VPA treatment. Ten days later, the patient recovered both clinically and laboratorial. Consequently, the patient was discharged with cure. In conclusion, AP is a rare, severe adverse reaction to VPA treatment. If a child, who is receiving VPA, develops abdominal pain and vomits, VPA-associated pancreatitis must be considered.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Valproinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Valproinsäure, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
2-Propylpentansäure
Supelco
Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Valproinsäure, European Pharmacopoeia (EP) Reference Standard